Search research articles
Contact Us
Filters
Showing results (121-130 of 293) with videos related to
Page
of 30
Sort By:
Molecular Oncology
|
August 25, 2014
Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study
Leonardo Tenori, Catherine Oakman, Patrick G Morris, et al.
Blood Cancer Journal
|
February 20, 2025
High WEE1 expression is independently linked to poor survival in multiple myeloma
Anish K Simhal, Ross S Firestone, Jung Hun Oh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 21, 2007
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience
Hyman B Muss, Donald A Berry, Constance Cirrincione, et al.
Cancer
|
August 16, 2016
Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up
Hannah Y Wen, Melissa Krystel-Whittemore, Sujata Patil, et al.
Breast Cancer Research and Treatment
|
May 31, 2019
Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy
Melissa Krystel-Whittemore, Jin Xu, Edi Brogi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 1995
Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer
L Vahdat, G Raptis, D Fennelly, et al.
Nature Communications
|
October 13, 2017
Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes
Nadeem Riaz, Pedro Blecua, Raymond S Lim, et al.
Breast Cancer Research and Treatment
|
September 8, 2011
Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer
Devika Gajria, Joseph Gonzalez, Kimberly Feigin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2012
Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?
Harold J Burstein, Martine J Piccart-Gebhart, Edith A Perez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 19, 2010
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea
Chau Dang, Nancy Lin, Beverly Moy, et al.
Page
of 30
Search research articles
Search
Showing results (121-130 of 293) with videos related to
Sort By:
Page
of 30
Molecular Oncology
|
August 25, 2014
Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study
Leonardo Tenori, Catherine Oakman, Patrick G Morris, et al.
Blood Cancer Journal
|
February 20, 2025
High WEE1 expression is independently linked to poor survival in multiple myeloma
Anish K Simhal, Ross S Firestone, Jung Hun Oh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 21, 2007
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience
Hyman B Muss, Donald A Berry, Constance Cirrincione, et al.
Cancer
|
August 16, 2016
Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up
Hannah Y Wen, Melissa Krystel-Whittemore, Sujata Patil, et al.
Breast Cancer Research and Treatment
|
May 31, 2019
Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy
Melissa Krystel-Whittemore, Jin Xu, Edi Brogi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 1995
Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer
L Vahdat, G Raptis, D Fennelly, et al.
Nature Communications
|
October 13, 2017
Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes
Nadeem Riaz, Pedro Blecua, Raymond S Lim, et al.
Breast Cancer Research and Treatment
|
September 8, 2011
Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer
Devika Gajria, Joseph Gonzalez, Kimberly Feigin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2012
Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?
Harold J Burstein, Martine J Piccart-Gebhart, Edith A Perez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 19, 2010
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea
Chau Dang, Nancy Lin, Beverly Moy, et al.
Page
of 30